Allo-aca TFA, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca TFA blocks leptin signaling and action in numerous in vitro and in vivo models^[1][2].

Allo-aca TFA inhibits leptin-induced proliferation of MDA-MB-231 cells at 50 pM concentration. Allo-aca TFA inhibits leptin-induced proliferation of MCF-7 cells with an IC₅₀ of 200 pM^[1].
Allo-aca TFA at 250 nmol/L reduces VEGF-dependent leptin mRNA expression in both cell lines below base levels. Allo-aca TFA inhibits VEGF mitogenic effects. Allo-aca TFA inhibits VEGF-induced chemotaxis and chemokinesis in RF/6A retinal endothelial cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In an MDA-MB-231 orthotopic mouse xenograft model, Allo-aca TFA administered subcutaneously significantly extends the average survival time from 15.4 days (untreated controls) to 24 and 28.1 days at 0.1 and 1mg/kg/day doses, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1188.21

C₅₀H₇₆F₃N₁₃O₁₇

{H-allo}-TE-{Nva}-VALSR-{Aca}-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Otvos L Jr, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011;47(10):1578-1584.

  [2]. Coroniti R, et al. Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models [published correction appears in Front Mol Biosci. 2016 Nov 18;3:75]. Front Mol Biosci. 2016;3:67. Published 2016 Oct 13.